Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CES1 | P23141 | 2/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | MMP2 | P08253 | 2/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | MMP14 | P50281 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3397979 | 0.83 | CA1 (0.33) | CA2CA1CES1CES2CA12 | |
| SCHEMBL2637263 | 0.76 | TSHR (0.38) | CA2CA1CES1CES2CA12 | |
| SCHEMBL2374254 | 0.74 | AKR1C3 (0.42) | CA2CA1CES1CES2CA12 | |
| SCHEMBL35321 | 0.74 | CA1 (0.55) | CA2CA1CES1CES2CA12 | |
| SCHEMBL11322611 | 0.72 | CA1 (0.53) | CA2CA1CES1CES2CA12 | |
| SCHEMBL3733671 | 0.72 | CA1 (0.53) | CA2CA1CES1CES2CA12 | |
| SCHEMBL2636710 | 0.71 | PGK1 (0.48) | — | |
| SCHEMBL3625606 | 0.71 | TSHR (0.42) | AKR1C3LMNATSHR | |
| SCHEMBL8600352 | 0.70 | IDO1 (0.39) | CA2CA1CES1CES2AKR1C3 | |
| SCHEMBL8133189 | 0.70 | GSK3B (0.42) | CA2CA1CES1AKR1C3MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10927135-B2 | Metal-free direct arylation of dialkyl phosphonates for the synthesis of mixed alkyl aryl phosphonates | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS (US) | 2021-02-23 | — | — | US | disclosed |
| US-20200255461-A1 | METAL-FREE DIRECT ARYLATION OF DIALKYL PHOSPHONATES FOR THE SYNTHESIS OF MIXED ALKYL ARYL PHOSPHONATES | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2020-08-13 | — | — | US | disclosed |
| WO-2019028391-A1 | METAL-FREE DIRECT ARYLATION OF DIALKYL PHOSPHONATES FOR THE SYNTHESIS OF MIXED ALKYL ARYL PHOSPHONATES | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS (US) | 2019-02-07 | — | — | WO | disclosed |
| EP-2438056-B1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI PHARMACEUTICALS LLC (US) | 2017-12-20 | — | — | EP | disclosed |
| US-9096624-B2 | Amino pyrimidine anticancer compounds | OSI Pharmaceuticals, LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-20130231306-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI Pharmaceuticals, LLC (US) | 2013-09-05 | — | — | US | disclosed |
| EP-2202308-B1 | Methods and compositions for polypeptide engineering | CODEXIS MAYFLOWER HOLDINGS LLC (US) | 2013-02-13 | — | — | EP | disclosed |
| EP-2480533-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| EP-2438056-A2 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI Pharmaceuticals, LLC (US) | 2012-04-11 | — | — | EP | disclosed |
| US-20120015820-A1 | METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING | CODEXIS MAYFLOWER HOLDINGS, LLC (US) | 2012-01-19 | — | — | US | disclosed |
| US-5654282-A | Selectin binding glycopeptides | GLYCOMED INCORPORATED (US) | 1997-08-05 | — | — | US | disclosed |
| US-5641865-A | SURFACTANT STABILIZED MICROHETEROGENEOUS DISPERSION OF AQUEOUS PHASE CONTAINING ANTIBODY OR FRAGMENT THEREOF IN WATER IMMISCIBLE MEDIUM | IGEN, INC. (US) | 1997-06-24 | — | — | US | disclosed |
| EP-0414755-B1 | INTERACTION SYSTEM COMPRISING A SURFACTANT-STABILIZED DISPERSE AQUEOUS PHASE CONTAINING AN ANTIBODY OR ANTIBODY FRAGMENT | IGEN INC (US) | 1996-10-16 | — | — | EP | disclosed |
| EP-0720619-A1 | SELECTIN BINDING GLYCOPEPTIDES | GLYCOMED INCORPORATED (US) | 1996-07-10 | — | — | EP | disclosed |
| US-5508387-A | Selectin binding glycopeptides | GLYCOMED INCORPORATED (US) | 1996-04-16 | — | — | US | disclosed |
| WO-1995004751-A1 | SELECTIN BINDING GLYCOPEPTIDES | GLYCOMED INCORPORATED (US) | 1995-02-16 | — | — | WO | disclosed |
| US-5314642-A | Hydrolysis | IGEN, INC. (US) | 1994-05-24 | — | — | US | disclosed |
| EP-0414755-A4 | INTERACTION SYSTEM COMPRISING A SURFACTANT-STABILIZED DISPERSE AQUEOUS PHASE CONTAINING AN ANTIBODY OR ANTIBODY FRAGMENT | — | 1991-12-11 | — | — | EP | disclosed |
| EP-0414755-A1 | INTERACTION SYSTEM COMPRISING A SURFACTANT-STABILIZED DISPERSE AQUEOUS PHASE CONTAINING AN ANTIBODY OR ANTIBODY FRAGMENT. | IGEN INC (US) | 1991-03-06 | — | — | EP | disclosed |
| WO-1989010142-A1 | INTERACTION SYSTEM COMPRISING A SURFACTANT-STABILIZED DISPERSE AQUEOUS PHASE CONTAINING AN ANTIBODY OR ANTIBODY FRAGMENT | IGEN, INC. (US) | 1989-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231306-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | DPYD, PTK2, TYMS | CA2 3519/4885CA1 4413/4885CES1 4588/4885 |
| US-20200255461-A1 | METAL-FREE DIRECT ARYLATION OF DIALKYL PHOSPHONATES FOR THE SYNTHESIS OF MIXED ALKYL ARYL PHOSPHONATES | SLC35B2, PPIP5K2, PPA1 | CA2 1238/4885CA1 2467/4885CES1 2454/4885 |
| US-10927135-B2 | Metal-free direct arylation of dialkyl phosphonates for the synthesis of mixed alkyl aryl phosphonates | SLC35B2, PPIP5K2, PPA1 | CA2 1238/4885CA1 2467/4885CES1 2454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.